.
.

Continuing Education Activities

Here at JADPRO CE, you can find a valuable array of accredited educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!

Topic

Format

      Quick Tips →

*Sorted by program start date
HEMATOLOGIC MALIGNANCIES
Live

Learn From the Experts About Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Gain insights and clinical knowledge on the science of new targeted therapies and immunotherapies for the treatment of hematologic malignancies. Learn how to manage the side effects and other clinical issues associated with these new treatments in a case-based, informal educational setting.

Posted: 3/10/2018 / Expires: 10/20/2018

Credits/Contact Hours: 6.5

IMMUNOTHERAPY
Live

Learn From the Experts About Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology

Learn about the immune system and immune checkpoint targets, as well as everything the oncology AP needs to know about managing immune-related adverse events.

Posted: 3/10/2018 / Expires: 10/20/2018

Credits/Contact Hours: 6.0

OVARIAN CANCER
Video

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

AML
Video

Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Take a deep dive into the updated WHO criteria for diagnosing myeloid malignancies, the mechanisms of action of new novel therapies, and the growing role of molecular mutations, while also learning how to take a collaborative, multidisciplinary approach to classifying these diseases. Advanced practitioners are key to managing the evolving continuum of myeloid malignancies and creating a multidisciplinary team approach to managing patients with complex myeloid malignancies.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

COLORECTAL CANCER
Video

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

CAR T-CELL THERAPY
Video

New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

Get an update on the fast-changing world of therapies for hematologic malignancies. With the constantly growing list of new drugs and indications, as well as the introduction of cutting-edge CAR T-cell therapy for the treatment of hematologic malignancies, it’s important that advanced practitioners stay up to date on the latest advances to be able to adequately diagnose, treat, and help patients navigate potential side effects.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

IRAES
Video

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

EGFR/NSCLC
Video

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Learn about the recent updates in the world of genetic testing and targeted therapies for non–small cell lung cancer. It’s vital that advanced practitioners in oncology have the latest knowledge on EGFR, ALK, and BRAF inhibitors, as well as acquired resistance mutations, to help patients from diagnosis through treatment.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

UROTHELIAL CARCINOMA
Video

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

SOFT TISSUE SARCOMAS
Video

Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Discover how to cultivate and personalize a multidisciplinary approach—involving the medical oncology, radiation, and surgical teams—to treating patients with soft tissue sarcoma in your own institution. In addition, get an update on the staging criteria and current state of systemic, surgical, and radiation therapy options for this disease. 

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

AML
Video

A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Hear from expert advanced practitioners about the updated WHO classification criteria and today’s leading-edge treatments for AML. Also learn about the molecular mutations commonly associated with this disease and how to identify patients who are genetically predisposed.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.5

DRUG DEVELOPMENT
Video

An Address From Dr. Richard Pazdur: How the Changing Landscape of Oncology Drug Development and Approval Will Affect Advanced Practice

Get an inside perspective on how the FDA updates its drug approval processes to reflect the changing oncology treatment environment and to incorporate the voice of the patient. With increasing numbers of oncology drug approvals and the ever-important area of molecularly targeted therapy, it is critical that advanced practitioners embrace and support this change.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.0

MULTIPLE MYELOMA
Video

Risk Stratification in Multiple Myeloma: Putting the Pieces Together

While the past few years have shown an unprecedented increase in the number of agents available to treat patients with multiple myeloma, many advanced practitioners struggle with optimal agent choice, timing, and sequencing, especially related to the use of these newer agents in combination regimens. Learn about these aspects of treatment, as well as testing and diagnosis, risk stratification, emerging toxicities, and supporting patients on oral therapies.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.5

BREAST CANCER
Video

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.

Posted: 1/22/2018 / Expires: 1/22/2019

Credits/Contact Hours: 1.5

CHRONIC LYMPHOCYTIC LEUKEMIA
Print

Understanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia

CLL is the most common leukemia in Western countries, with a  population primarily over 70 years of age. Frailty and comorbidities are common concerns with established chemoimmunotherapy, but new FDA-approved therapies have led to specialized, specific treatments for the different stages of CLL. 

Posted: 12/19/2017 / Expires: 12/18/2018

Credits/Contact Hours: 3.0

ORAL ONCOLYTICS
Video

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources.  This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens. 

Posted: 12/8/2017 / Expires: 12/7/2018

Credits/Contact Hours: 1.0

ORAL ONCOLYTICS
Print

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources.  This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens. 

Posted: 12/8/2017 / Expires: 12/7/2018

Credits/Contact Hours: 1.0

IMMUNOTHERAPY
Video

Overview of Immunotherapy

Understanding the basic science behind agents is important for understanding the potential side effects of these agents. In this overview of the immune system, key concepts in immunology and the mechanisms of action of anti–CTLA-4, anti–PD-1, and anti–PD-L1 inhibitors are reviewed.

Posted: 12/1/2017 / Expires: 11/30/2018

Credits/Contact Hours: 2.25

RENAL CELL CARCINOMA
Video

Case Studies in Renal Cell Carcinoma

Renal cell carcinoma is an immunotherapy responsive cancer that has had an explosion of new therapies, in both small molecule and immunotherapy approaches.

Posted: 12/1/2017 / Expires: 11/30/2018

Credits/Contact Hours: 0.5

MELANOMA
Video

Case Studies in Melanoma

The landscape for melanoma has changed dramatically in the past several years. Newly approved immunotherapies offer new options for clinicians. A case study of a stage IV melanoma patient includes a description of clinicians’ management of immune-mediated adverse events.

Posted: 12/1/2017 / Expires: 11/30/2018

Credits/Contact Hours: 0.5

HEAD AND NECK CANCER
Video

Case Studies in Head and Neck Cancer

Clinical trial findings for two immunotherapies approved for patients with head and neck cancer, pembrolizumab and nivolumab, are presented, along with a review of early and latent adverse effects associated with these immunotherapeutic agents that advanced practitioners should be aware of.

Posted: 12/1/2017 / Expires: 11/30/2018

Credits/Contact Hours: 0.5

NSCLC
Video

An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

An expert roundtable discussion reviewing key cell signaling pathways involved with NSCLC, specifically with regard to diagnosis, molecular testing, targeted therapies, immunotherapies, and the anticipation and management of adverse events.

Posted: 11/21/2017 / Expires: 11/21/2018

Credits/Contact Hours: 1.0

BIOSIMILARS
Print

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Over the past two decades, biologics have had a huge impact on the treatment of cancer in multiple tumor types, and in many cases these agents have improved outcomes and survival. In oncology, a growing number of biosimilars have been approved and are in clinical use, with more in the FDA pipeline.

Posted: 11/16/2017 / Expires: 11/16/2018

Credits/Contact Hours: 0.75

MOLECULAR TESTING
Print

The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer

A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of non–small cell lung cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy. 

Posted: 10/19/2017 / Expires: 10/18/2018

Credits/Contact Hours: 1.0

MOLECULAR TESTING
Print

The Emerging Role of Molecular Testing in Ovarian Cancer

 A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of ovarina cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy. 

Posted: 10/19/2017 / Expires: 10/18/2018

Credits/Contact Hours: 1.0

MOLECULAR TESTING
Video

The Emerging Role of Molecular Testing in an Era of Precision Medicine - Non-Small Cell Lung Cancer

In the past 10 years, the FDA has approved several new medications to treat patients with genetic alterations, and new technology has made sequencing more affordable and convenient. Representative members of a patient care team—a medical oncologist, a clinical pharmacy specialist, and a nurse practitioner—come together in this roundtable to discuss the growing role of molecular testing in the treatment of patients with non–small cell lung cancer.

Posted: 10/18/2017 / Expires: 10/18/2018

Credits/Contact Hours: 1.0

GYNECOLOGIC ONCOLOGY
Print

Genetic Counseling in Gynecologic Oncology: What Advanced Practitioners Need to Know

The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Because of this, genetic counseling is strongly recommended. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.

Posted: 10/17/2017 / Expires: 10/16/2018

Credits/Contact Hours: 1.5

MOLECULAR TESTING
Video

The Emerging Role of Molecular Testing in an Era of Precision Medicine - Ovarian Cancer

The trend toward identifying biomarkers for early detection and to determine drug response in patients with ovarian cancer is providing opportunities for better patient outcomes. In this roundtable discussion, key members of the health-care team discuss the role advanced practitioners can take in promoting molecular testing to appropriate patients and educating patients and their families on complex issues involving genetic testing and treatment selection.

Posted: 10/12/2017 / Expires: 10/12/2018

Credits/Contact Hours: 1.0

CAR T-CELL THERAPY
Print

The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias

The development of tumor-targeted chimeric antigen receptor (CAR)–modified T cells has demonstrated the potential of this therapy for certain patients with refractory or relapsed leukemias and lymphomas. This article discusses the design of first- and second-generation CARs, their proposed MOAs, and key associated toxicities. As clinical use of this technology progresses, advanced practitioners will need to understand the biology underlying CAR T-cell therapy and play crucial roles in managing treatment-related toxicities.

 

Posted: 9/12/2017 / Expires: 9/11/2018

Credits/Contact Hours: 1.0

MULTIPLE MYELOMA
Video

Updates in Multiple Myeloma

This presentation educates and informs the advanced practitioner on updates in multiple myeloma (MM) using case studies of patients with newly diagnosed and relapsed/refractory MM. Strategies for the management of patients with MM, including diagnostic workup, staging, and how to maximize therapies by mitigating adverse events are presented. Recent FDA approvals for agents for the treatment of MM are also reviewed.

Posted: 7/28/2017 / Expires: 7/28/2018

Credits/Contact Hours: 1.0

CHRONIC LYMPHOCYTIC LEUKEMIA
Video

Updates in Chronic Lymphocytic Leukemia

As an integral member of the collaborative practice team, advanced practitioners must maintain a wide knowledge base to effectively treat patients with B-cell malignancies, including patients with chronic lymphocytic leukemia (CLL). Learn about the management of patients with newly diagnosed and relapsed/refractory CLL, as well as monitoring parameters for toxicities associated with newer agents. The presentation also addresses the management of CLL-related complications such as infection and tumor lysis syndrome.

Posted: 7/28/2017 / Expires: 7/28/2018

Credits/Contact Hours: 1.0

HODGKIN LYMPHOMA
Video

Updates in Hodgkin Lymphoma

Novel agents for the treatment of Hodgkin lymphoma have changed the treatment landscape for this disease. Topics in this presentation include principles of risk-stratified treatment and keys to optimal patient management for immune checkpoint inhibitors. As the disease that arguably set off the survivorship movement, common late effects such as cardiovascular disease and steps for follow-up are reviewed.

Posted: 7/28/2017 / Expires: 7/28/2018

Credits/Contact Hours: 1.0

NON-HODGKIN LYMPHOMA
Video

Updates in Non-Hodgkin Lymphoma

This case-based presentation covers practical information for advanced practitioners caring for this patient population, including general principles for the treatment of common subtypes of Non-hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma). In addition, supportive care issues such as the management of anthracycline-induced cardiomyopathy and cardiotoxicity are addressed.

Posted: 7/28/2017 / Expires: 7/28/2018

Credits/Contact Hours: 1.0

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.